OR WAIT null SECS
September 19, 2023
The agency’s work with EUnetHTA 21 helped it to prepare the EU for implementation of the regulation.
Iopofosine provides targeted delivery of idodine-131 directly to cancer cells.
September 15, 2023
The safety profile of erdafitinib observed in THOR was consistent with the previously reported safety profile of erdafitinib in metastatic urothelial carcinoma (mUC).
September 06, 2023
Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.
September 02, 2023
The ACT EU initiative aims to develop the European Union further as a competitive centre for innovative clinical research.
August 31, 2023
The updated vaccine will be ready to ship following a positive European Commission review.
August 24, 2023
The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.
August 18, 2023
The assessment aims to determine whether valproate use in men could lead to neurodevelopmental disorders in their children.
August 17, 2023
The indication for Pombiliti is a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
August 02, 2023
Current good manufacturing practices for oral solid dosage forms protect the product from contamination and potential errors.